Expression, purification and characterization of the interferon-inducible, antiviral and tumour-suppressor protein, human RNase L

Journal of Biosciences

Volumn 37, Issue 1, 2012, Pages 103-113

  Gupta, Ankush ^a   Rath, Pramod C ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

2 5A; antiviral function; cellular RNA degradation; interferons; recombinant RNase L

Indexed keywords

RECOMBINANT RIBONUCLEASE L; RIBONUCLEASE L; UNCLASSIFIED DRUG;

APOPTOSIS; BIOCHEMISTRY; CELL ORGANELLE; CHROMATOGRAPHY; COLIFORM BACTERIUM; DEGRADATION; PROTEIN; PURIFICATION; RNA; TUMOR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CANCER INHIBITION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME PURIFICATION; ESCHERICHIA COLI; HUMAN; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; BLOTTING, WESTERN; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDORIBONUCLEASES; ESCHERICHIA COLI; HUMANS; MICE; ORGANIC ANION TRANSPORTERS; RECOMBINANT FUSION PROTEINS; RNA STABILITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

MAMMALIA;

EID: 84863396515     PISSN: 02505991     EISSN: 09737138     Source Type: Journal    
DOI: 10.1007/s12038-011-9180-4     Document Type: Article

References (44)

1. Al-Ahmadi W, Al-Haj L, Al-Mohanna FA, Silverman RH and Khabar KSA 2009 RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth. Oncogene 28 1782-1791
2. Anderson BR, Muramatsu H, Jha BK, Silverman RH, Weissman D and Karikó K 2011 Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 39 9329-9338
3. Auffray C and Rougeon F 1980 Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur. J. Biochem. 107 303-314
4. Bisbal C and Salehzada T 2008 RNase L, a crucial mediator of innate immunity and other cell functions [original article in French]. Med. Sci. (Paris) 24 859-864
5. Bisbal C and Silverman RH 2007 Diverse functions of RNase L and implications in pathology. Biochimie 89 789-798
6. Castelli JC, Hassel BA, Wood KA, Li XL, Amemiya K, Dalakas MC, Torrence PF and Youle RJ 1997 A study of the interferon antiviral mechanism: Apoptosis activation by the 2-5A system. J. Exp. Med. 186 967-972 (Pubitemid 27407357)
7. Chakrabarti A, Jha BK and Silverman RH 2011 New insights into the role of RNase L in innate immunity. J. Interferon Cytokine Res. 31 49-57
8. Díaz Guerra M, Esteban M and Martínez JL 1997 Growth of Escherichia coli in acetate as a sole carbon source is inhibited by ankyrin-like repeats present in the 2′,5′-linked oligoadenylate-dependent human RNase L enzyme. FEMS Microbiol. Lett. 149 107-113 (Pubitemid 27130165)
9. Dong B and Silverman RH 1995 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J. Biol. Chem. 270 4133-4137
10. Dong B and Silverman RH 1997 A bipartite model of 2-5A-dependent RNase L. J. Biol. Chem. 272 22236-22242 (Pubitemid 27382855)
11. Dong B and Silverman RH 1999 Alternative function of a protein kinase homology domain in 2′,5′-oligoadenylate dependent RNase L. Nucleic Acids Res. 27 439-445 (Pubitemid 29210006)
12. Dong B, Xu L, Zhou A, Hassel BA, Lee X, Torrence PF and Silverman RH 1994 Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J. Biol. Chem. 269 14153-14158 (Pubitemid 24191172)
13. Dong B, Niwa M, Walter P and Silverman RH 2001 Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p. RNA 7 361-373 (Pubitemid 32381912)
14. Frémont M, El Bakkouri K, Vaeyens F, Herst CV, De Meirleir K and Englebienne P 2005 2′,5′-oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. Exp. Mol. Pathol. 78 239-246 (Pubitemid 40740226)
15. Hassel BA, Zhou A, Sotomayor C, Maran A and Silverman RH 1993 A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J. 12 3297-3304 (Pubitemid 23232761)
16. Hovanessian AG and Justesen J 2007 The human 2′- 5′oligoadenylate synthetase family: Unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie 89 779-788 (Pubitemid 47001635)
17. Jha BK, Polyakova I, Kessler P, Dong B, Dickerman B, Sen GC and Silverman RH 2011 Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. J. Biol. Chem. 286 26319-26326
18. Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R 2011 The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities. J. Interferon Cytokine Res. 31 41-47
19. Le Roy F, Salehzada T, Bisbal C, Doughearty JP and Peltz SW 2005 A newly discovered function for RNase L in regulating translation termination. Nat. Struct. Mol. Biol. 12 505-512 (Pubitemid 43085880)
20. Le Roy F, Silhol M, Salehzada T and Bisbal C 2007 Regulation of mitochondrial mRNA stability by RNase L is translation-dependent and controls IFN-alpha induced apoptosis. Cell Death Differ. 14 1406-1413 (Pubitemid 47086729)
21. Li G, Xiang Y, Sabapathy K and Silverman RH 2004 An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J. Biol. Chem. 279 1123-1131 (Pubitemid 38082634)
22. Li XL, Andersen JB, Ezelle HJ, Wilson GM and Hassel BA 2007 Post-transcriptional regulation of RNase-L expression is mediated by the 3′-untranslated region of its mRNA. J. Biol. Chem. 282 7950-7960 (Pubitemid 47093551)
23. Li XL, Ezelle HJ, Kang TJ, Zhang L, Shirey KA, Harro J, Hasday JD, Mohapatra SK, et al. 2008 An essential role for the antiviral endoribonuclease, RNase L, in antibacterial immunity. Proc. Natl. Acad. Sci. USA 105 20816-20821
24. Liang SL, Quirk D and Zhou A 2006 RNase L: Its biological roles and regulation. IUBMB Life 58 508-514 (Pubitemid 44470236)
25. Liu W, Liang SL, Liu H, Silverman R and Zhou A 2007 Tumour suppressor function of RNase L in a mouse model. Eur. J. Cancer 43 202-209 (Pubitemid 46054467)
26. Luthra P, Sun D, Silverman RH and He B 2011 Activation of IFN-β expression by a viral mRNA through RNase L and MDA5. Proc. Natl. Acad. Sci. USA 108 2118-2123
27. Madsen BE, Ramos EM, Boulard M, Duda K, Overgaard J, Nordsmark M, Wiuf C and Hansen LL 2008 Germline mutation in RNASEL predicts increased risk of head and neck, uterine cervix and breast cancer. PLoS ONE 3 e2492
28. Malathi K, Dong B, Gale M Jr and Silverman RH 2007 Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 448 816-819 (Pubitemid 47266340)
29. Malathi K, Saito T, Crochet N, Barton DJ, Gale M Jr and Silverman RH 2010 RNase L releases a small RNA from HCV RNA that refolds into a potent PAMP. RNA 16 2108-2119
30. Morin B, Rabah N, Boretto-Soler J, Tolou H, Alvarez K and Canard B 2010 High yield synthesis, purification and characterisation of the RNase L activators 5′-triphosphate 2′-5′- oligoadenylates. Antiviral Res. 87 345-352.
31. Nakanishi M, Yoshimura A, Ishida N, Ueno Y and Kitade Y 2004 Contribution of Tyr712 and Phe716 to the activity of human RNase L. Eur. J. Biochem. 271 2737-2744 (Pubitemid 38869974)
32. Nakanishi M, Goto Y and Kitade Y 2005 2-5A induces a conformational change in the ankyrin-repeat domain of RNase L. Proteins 60 131-138 (Pubitemid 40734757)
33. Pandey M and Rath PC 2004 Expression of interferon-inducible recombinant human RNase L causes RNA degradation and inhibition of cell growth in Escherichia coli. Biochem. Biophys. Res. Commun. 317 586-597 (Pubitemid 38452523)
34. Pandey M and Rath PC 2007 Organization of the interferon-inducible 2′,5′-oligoadenylate-dependent ribonuclease L (RNase L) gene of mouse. Mol. Biol. Rep. 34 97-104 (Pubitemid 46675274)
35. Pandey M, Bajaj GD and Rath PC 2004 Induction of the interferon-inducible RNA-degrading enzyme, RNase L, by stress-inducing agents in the human cervical carcinoma cells. RNA Biol. 1 21-27
36. Player MR, Wondrak EM, Bayly SF and Torrence PF 1998 Ribonuclease L, a 2-5A-dependent enzyme: Purification to homogeneity and assays for 2-5A binding and catalytic activity. Methods 15 243-253
37. Sadler AJ and Williams BRG 2008 Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8 559-568 (Pubitemid 351913674)
38. Silverman RH 2003 Implications for RNase L in prostate cancer biology. Biochemistry 42 1805-1812 (Pubitemid 36258654)
39. Silverman RH 2007 A scientific journey through the 2-5A/RNase L system. Cytokine Growth Factor Rev. 18 381-388 (Pubitemid 47302833)
40. Sugiyama C, Kuramoto N, Nagashima R, Yoneyama M and Ogita K 2008 Enhanced expression of RNase L as a novel intracellular signal generated by NMDA receptors in mouse cortical neurons. Neurochem. Int. 53 71-78
41. Tanaka N, Nakanishi M, Kusakabe Y, Goto Y, Kitade Y and Nakamura KT 2004 Structural basis for recognition of 2′,5′-linked oligoadenylates by human ribonuclease L. EMBO J. 23 3929-3938 (Pubitemid 39472415)
42. Yoshimura A, Nakanishi M, Yatome C and Kitade Y 2002 Comparative study on the biological properties of 2′,5′- oligoadenylate derivatives with purified human RNase L expressed in E. coli. J. Biochem. 132 643-648 (Pubitemid 35238919)
43. Zhou A, Hassel BA and Silverman RH 1993 Expression cloning of 2-5A-dependent RNAase: A uniquely regulated mediator of interferon action. Cell 72 753-765 (Pubitemid 23093883)
44. Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C and Silverman RH 1997 Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J. 16 6355-6363 (Pubitemid 27483262)